TG治疗公司将Hercules Capital提供的贷款增加到2亿美元；成交时提取了7000万美元

09:18 AM EST, 01/04/2022 (MT Newswires) -- TG Therapeutics (TGTX) said Tuesday it amended its term loan with Hercules Capital (HTGC) to increase the facility size to $200 million from $60 million, with $70 million drawn at closing on Dec. 30, 2021.

TG Therapeutics said the remaining $130 million may be drawn in three tranches.

The first tranche is available upon the US Food and Drug Administration's approval of the supplemental new drug application and biologics license agreement for the ublituximab and umbralisib combination to treat chronic lymphocytic leukemia.

The second tranche is available upon the FDA's approval of the biologics license agreement for ublituximab to treat relapsing forms of multiple sclerosis, and the third tranche is available to back other company initiatives, subject to Hercules Capital approval.

Price: 20.5, Change: +0.05, Percent Change: +0.24